FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
The Veterinary record1984; 114(15); 369-374; doi: 10.1136/vr.114.15.369

Trials of an inactivated equid herpesvirus 1 vaccine: challenge with a subtype 1 virus.

Abstract: Vaccinated yearlings , two-year-old and in-foal pony mares with appropriate controls were exposed to aerosols of a subtype 1 virus one to two months after two or three vaccinations; all became infected. No obvious differences in the febrile responses, clinical signs and subsequent abortions were found between vaccinated and control mares. All vaccinated yearlings and two-year-old ponies developed a febrile respiratory disease but this was less severe than that suffered by the controls and the amounts and duration of virus shedding were reduced.
Get Full Text
Publication Date: 1984-04-14 PubMed ID: 6328728DOI: 10.1136/vr.114.15.369Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Comparative Study
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article investigates the effectiveness of a vaccine against equid herpesvirus 1 (EHV-1) in young horses and pregnant mares. Despite vaccinations, all test animals still became infected when exposed to the virus, but the vaccinated young horses and two-year-olds experienced milder symptoms and shed the virus for shorter periods.

Methodology and Study Groups

  • The study involved yearlings, two-year-old horses, and pregnant pony mares. Some of the animals were vaccinated against EHV-1, while others served as non-vaccinated controls for comparison.
  • Approximately one to two months after receiving two or three doses of the EHV-1 vaccine, all animals were intentionally exposed to the virus through aerosols.

Observations and Findings

  • All animals, regardless of their vaccination status, became infected after exposure to EHV-1. This demonstrates that the vaccine does not fully prevent EHV-1 infection.
  • No significant differences were noted in the febrile responses, clinical signs, and number of future miscarriages between vaccinated and control mares, suggesting that the vaccine had limited or no protective effect in this particular group.
  • In contrast, while vaccinated yearlings and two-year-old horses also developed febrile (feverish) respiratory disease, their symptoms were less severe than those in the non-vaccinated control group.
  • Furthermore, the vaccinated yearlings and two-year-old horses shed the virus for shorter durations and in smaller amounts compared to the non-vaccinated control group. This indicates that, while the vaccine doesn’t prevent infection, it may limit virus replication and improve disease outcomes in these younger horses.

Implications of the Study

  • The EHV-1 vaccine appears to be partially effective by ameliorating disease severity and reducing virus shedding in vaccinated yearlings and two-year-old horses.
  • However, the protection seems to be less effective in pregnant pony mares, with the vaccine not significantly lowering the risk of miscarriage, an important consideration as EHV-1 can cause abortion in equines.
  • Further research is needed to improve the EHV-1 vaccine and extend its protection more effectively across all age and demographic groups of horses.

Cite This Article

APA
Burrows R, Goodridge D, Denyer MS. (1984). Trials of an inactivated equid herpesvirus 1 vaccine: challenge with a subtype 1 virus. Vet Rec, 114(15), 369-374. https://doi.org/10.1136/vr.114.15.369

Publication

The Veterinary record
ISSN: 0042-4900
NlmUniqueID: 0031164
Country: England
Language: English
Volume: 114
Issue: 15
Pages: 369-374

Researcher Affiliations

Burrows, R
    Goodridge, D
      Denyer, M S

        MeSH Terms

        • Abortion, Veterinary / prevention & control
        • Animals
        • Antibodies, Viral / biosynthesis
        • Clinical Trials as Topic / veterinary
        • Female
        • Herpesviridae / immunology
        • Herpesviridae Infections / immunology
        • Herpesviridae Infections / prevention & control
        • Herpesviridae Infections / veterinary
        • Herpesvirus 1, Equid / immunology
        • Horse Diseases / immunology
        • Horse Diseases / prevention & control
        • Horses
        • Pregnancy
        • Vaccination / veterinary
        • Vaccines, Attenuated / immunology
        • Viral Vaccines / immunology
        • Viremia / prevention & control
        • Viremia / veterinary

        Citations

        This article has been cited 17 times.
        1. Allkofer A, Garvey M, Ryan E, Lyons R, Ryan M, Lukaseviciute G, Walsh C, Venner M, Cullinane A. Primary vaccination in foals: a comparison of the serological response to equine influenza and equine herpesvirus vaccines administered concurrently or 2 weeks apart. Arch Virol 2021 Feb;166(2):571-579.
          doi: 10.1007/s00705-020-04846-6pubmed: 33410993google scholar: lookup
        2. Day MJ, Carey S, Clercx C, Kohn B, MarsilIo F, Thiry E, Freyburger L, Schulz B, Walker DJ. Aetiology of Canine Infectious Respiratory Disease Complex and Prevalence of its Pathogens in Europe. J Comp Pathol 2020 Apr;176:86-108.
          doi: 10.1016/j.jcpa.2020.02.005pubmed: 32359641google scholar: lookup
        3. Kim SK, Shakya AK, O'Callaghan DJ. Intranasal treatment with CpG-B oligodeoxynucleotides protects CBA mice from lethal equine herpesvirus 1 challenge by an innate immune response. Antiviral Res 2019 Sep;169:104546.
          doi: 10.1016/j.antiviral.2019.104546pubmed: 31247247google scholar: lookup
        4. Kim SK, Shakya AK, O'Callaghan DJ. Immunization with Attenuated Equine Herpesvirus 1 Strain KyA Induces Innate Immune Responses That Protect Mice from Lethal Challenge. J Virol 2016 Sep 15;90(18):8090-104.
          doi: 10.1128/JVI.00986-16pubmed: 27356904google scholar: lookup
        5. Smith PM, Kahan SM, Rorex CB, von Einem J, Osterrieder N, O'Callaghan DJ. Expression of the full-length form of gp2 of equine herpesvirus 1 (EHV-1) completely restores respiratory virulence to the attenuated EHV-1 strain KyA in CBA mice. J Virol 2005 Apr;79(8):5105-15.
          doi: 10.1128/JVI.79.8.5105-5115.2005pubmed: 15795295google scholar: lookup
        6. Smith PM, Zhang Y, Grafton WD, Jennings SR, O'Callaghan DJ. Severe murine lung immunopathology elicited by the pathogenic equine herpesvirus 1 strain RacL11 correlates with early production of macrophage inflammatory proteins 1alpha, 1beta, and 2 and tumor necrosis factor alpha. J Virol 2000 Nov;74(21):10034-40.
          doi: 10.1128/jvi.74.21.10034-10040.2000pubmed: 11024132google scholar: lookup
        7. Bartels T, Steinbach F, Hahn G, Ludwig H, Borchers K. In situ study on the pathogenesis and immune reaction of equine herpesvirus type 1 (EHV-1) infections in mice. Immunology 1998 Mar;93(3):329-34.
          doi: 10.1046/j.1365-2567.1998.00451.xpubmed: 9640242google scholar: lookup
        8. Smith PM, Zhang Y, Jennings SR, O'Callaghan DJ. Characterization of the cytolytic T-lymphocyte response to a candidate vaccine strain of equine herpesvirus 1 in CBA mice. J Virol 1998 Jul;72(7):5366-72.
          doi: 10.1128/JVI.72.7.5366-5372.1998pubmed: 9620990google scholar: lookup
        9. Charan S, Palmer K, Chester P, Mire-Sluis AR, Meager A, Edington N. Transforming growth factor-beta induced by live or ultraviolet-inactivated equid herpes virus type-1 mediates immunosuppression in the horse. Immunology 1997 Apr;90(4):586-91.
          doi: 10.1046/j.1365-2567.1997.00202.xpubmed: 9176113google scholar: lookup
        10. Tewari D, Gibson JS, Slater JD, O'Neill T, Hannant D, Allen GP, Field HJ. Modulation of the serological response of specific pathogen-free (EHV-free) foals to EHV-1 by previous infection with EHV-4 or a TK-deletion mutant of EHV-1. Arch Virol 1993;132(1-2):101-20.
          doi: 10.1007/BF01309846pubmed: 8394686google scholar: lookup
        11. Allen G, Yeargan M, Costa LR, Cross R. Major histocompatibility complex class I-restricted cytotoxic T-lymphocyte responses in horses infected with equine herpesvirus 1. J Virol 1995 Jan;69(1):606-12.
          doi: 10.1128/JVI.69.1.606-612.1995pubmed: 7983765google scholar: lookup
        12. Sinclair R, Moult BJ, Mumford JA. Characterization of an antigenic site on glycoprotein 13 (gC) of equid herpesvirus type-1. Arch Virol 1993;129(1-4):327-36.
          doi: 10.1007/BF01316908pubmed: 7682404google scholar: lookup
        13. Bridges CG, Ledger N, Edington N. The characterization of equine herpes virus-1-infected cell polypeptides recognized by equine lymphocytes. Immunology 1988 Feb;63(2):193-8.
          pubmed: 2832309
        14. Bridges CG, Edington N. Genetic restriction of cytolysis during equid herpesvirus 1 subtype 2 infection. Clin Exp Immunol 1987 Nov;70(2):276-82.
          pubmed: 2827921
        15. Gibson JS, Slater JD, Awan AR, Field HJ. Pathogenesis of equine herpesvirus-1 in specific pathogen-free foals: primary and secondary infections and reactivation. Arch Virol 1992;123(3-4):351-66.
          doi: 10.1007/BF01317269pubmed: 1314051google scholar: lookup
        16. Pusterla N, Dorman DC, Burgess BA, Goehring L, Gross M, Osterrieder K, Soboll Hussey G, Lunn DP. Viremia and nasal shedding for the diagnosis of equine herpesvirus-1 infection in domesticated horses. J Vet Intern Med 2024 May-Jun;38(3):1765-1791.
          doi: 10.1111/jvim.16958pubmed: 38069548google scholar: lookup
        17. Osterrieder K, Dorman DC, Burgess BA, Goehring LS, Gross P, Neinast C, Pusterla N, Hussey GS, Lunn DP. Vaccination for the prevention of equine herpesvirus-1 disease in domesticated horses: A systematic review and meta-analysis. J Vet Intern Med 2024 May-Jun;38(3):1858-1871.
          doi: 10.1111/jvim.16895pubmed: 37930113google scholar: lookup
        Subscribe to our newsletter
        Join 99,780 horse owners like you who receive our email updates on horse health and nutrition.